- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab
-
- MIMURA Naoya
- Divison of Hematology-Oncology, Chiba Cancer Center
-
- KOJIMA Hiroshige
- Department of Gastroenterology, NHO Chiba East Hospital
-
- TSUJIMURA Hideki
- Divison of Hematology-Oncology, Chiba Cancer Center
-
- ISE Mikiko
- Divison of Hematology-Oncology, Chiba Cancer Center
-
- SAKAI Chikara
- Divison of Hematology-Oncology, Chiba Cancer Center
-
- FUKAI Kenichi
- Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University
-
- YOKOSUKA Osamu
- Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University
-
- KUMAGAI Kyoya
- Divison of Hematology-Oncology, Chiba Cancer Center
Bibliographic Information
- Other Title
-
- リツキシマブ併用化学療法後のB型肝炎ウイルス再活性化への対策
- リツキシマブ ヘイヨウ カガク リョウホウ ゴ ノ Bガタ カンエン ウイルス サイカッセイカ エ ノ タイサク
Search this article
Description
Reactivation of hepatitis B virus (HBV) has been recognized as one of the most serious complications in patients receiving chemotherapy with rituximab. From October 2007 to December 2008, rituximab was administered to 123 B-cell lymphoma patients in our institute. Four patients with positive hepatitis B surface antigen (HBsAg) received preemptive entecavir, and none of them developed HBV reactivation. For 26 patients whose hepatitis B surface antibody (HBsAb) and/or hepatitis B core antibody (HBcAb) were positive, HBV-DNA was monitored for one year after completion of chemotherapy. During this period, HBV reactivation was observed in two patients. Hepatitis was prevented in one patient by the administration of entecavir at the time HBV-DNA turns positive. Another developed de novo hepatitis B due to failure of monitoring. Preemptive entecavir for HBsAg positive patients and HBV-DNA monitoring for HBsAb and/or HBcAb positive patients seem to be effective.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 51 (3), 213-215, 2010
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680011591168
-
- NII Article ID
- 10026332467
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 10637367
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- CiNii Articles
-
- Abstract License Flag
- Disallowed